Formulations containing hyaluronic acid
CA 2061703 C · Owner: Hyal Pharmaceutical Corporation · Inventors: Klein, Ehud S.; Asculai, Samuel Simon; Falk, Rudolf E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Topically applied transdermally quick penetrating (best targeting the epidermis and subsequently remaining there for a prolonged period of time) systemic independent acting, combinations and formulations which employ combine, or, incorporate a therapeutically effective non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis together with an amount of hyaluronic acid and/or salts thereof (for example the sodium salt) and/or homologues analogues, derivatives, complexes, esters fragments, and/or sub units of, hyaluronic acid to treat a disease and condition of the skin and exposed tissue for example, basal cell carcinoma the, precancerous, often recurrent, actinic …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 20, 1992 and granted July 2, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 20, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 20, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.